News

Filter

Current filters:

VivusQsymia

1 to 9 of 18 results

Vivus says Actavis has filed ANDA for generic Qsymia

Vivus says Actavis has filed ANDA for generic Qsymia

10-05-2014

US drug developer Vivus disclosed on Friday that the company had received notice from generics major…

ActavisGenericsMetabolicsPatentsQsymiaRegulationUSAVivus

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients

10-10-2013

New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…

DiabetesMetabolicsPharmaceuticalQsymiaResearchVivus

Market for obesity therapies to reach a value of $2.6 billion in 2019

16-09-2013

The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report

05-09-2013

The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Law suit threat for Vivus over battle for shareholders' votes

17-07-2013

The battle has heated up between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

FinancialNorth AmericaPharmaceuticalQsymiaVivus

Vivus offers a compromise to end the proxy contest

14-07-2013

US drugmaker Vivus (Nasdaq: VVUS) said on Saturday (July 13) that it had communicated to Sam Colin and…

ManagementPharmaceuticalQsymiaVivus

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

1 to 9 of 18 results

COMPANY SPOTLIGHT

Menarini

Back to top